Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biotechnical Methods Section BTS
  • Published:

Biotechnical Methods Section (BTS)

Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia

Leukemia volume 14, pages 316–323 (2000)Cite this article

Abstract

A certain quantity of residual leukemic cells at several time points during chemotherapy of childhood acute lymphoblastic leukemia (ALL) was proved to predict outcome. Future childhood ALL treatment will take minimal residual disease (MRD) into consideration for stratification aiming at an individualization of chemotherapeutic regimens. Recently, the first quantitative real-time PCR assay for MRD detection was described using T cell receptor and immunoglobulin gene rearrangements as clonal markers. Quantitative real-time PCR was performed with TaqMan technology. Here, we present for the first time the potential of LightCycler real-time PCR technology to quantify MRD. We compare and assess different approaches for real-time PCR quantification of leukemic cells, based either on clone-specific primers and general fluorescence detection with SYBR Green, TaqMan probe or hybridization probes, or based on general PCR amplification and clone-specific detection with hybridization probes. MRD quantification with LightCycler real-time PCR technology is a sensitive, specific and incomparably rapid method that needs no post-PCR handling, hence eliminating contamination risk and saving time. Working towards the establishment of MRD quantification in routine diagnostics and towards treatment strategies based on these results, LightCycler quantitative PCR seems to be a promising new technique that makes results immediately available for treatment decisions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group (see comments) New Engl J Med 1998 339: 591–598

    Article  CAS  Google Scholar 

  2. van Dongen JJ, Seriu T, Panzer Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does van den Berg A, Hop WC, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352: 1731–1738

    Article  CAS  Google Scholar 

  3. Biondi A, Yokota S, Hansen Hagge TE, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Masera G, Bartram CR . Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse Leukemia 1992 6: 282–288

    CAS  PubMed  Google Scholar 

  4. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction (see comments) Lancet 1994 343: 196–200

    Article  CAS  Google Scholar 

  5. Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, Grandage VL, Rowbottom AW, Green AF, Clarke E, Lankester AW, Potter MN, Cornish JM, Pamphilon DH, Steward CG, Oakhill A . Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia Br J Haematol 1998 102: 860–871

    Article  CAS  Google Scholar 

  6. van Dongen JJ, Szczepanski T, de Bruijn MA, van den Beemd MW, de Bruin Versteeg S, Wijkhuijs JM, Tibbe GJ, van Gastel Mol EJ, Groeneveld K, Hooijkaas H . Detection of minimal residual disease in acute leukemia patients Cytok Mol Ther 1996 2: 121–133

    CAS  Google Scholar 

  7. Sczepanski TBA, Pongers-Willemse MJ, Hählen K, Van Wering ER, Wijkhuijs AJM, Tibbe GJM, De Bruijn MAC, Van Dongen JJM . Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease Leukemia 1999 13: 196–205

    Article  Google Scholar 

  8. Seriu T, Erz D, Stark Y, Bartram CR . T cell receptor Dδ2 Dδ3 rearrangement: a suitable allele-specific marker for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 1997 11: 759–761

    Article  CAS  Google Scholar 

  9. Ouspenskaia MVJD, Roberts WM, Estrov Z, Zipf TF . Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved Leukemia 1995 9: 321–328

    CAS  PubMed  Google Scholar 

  10. Sykes PJNS, Brisco MJ, Hughes E, Condon J, Morley AA . Quantitation of targets of PCR by use of limiting dilution Biotechniques 1992 13: 444–449

    CAS  PubMed  Google Scholar 

  11. Cave H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes Blood 1994 83: 1892–1902

    CAS  PubMed  Google Scholar 

  12. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ . Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes Leukemia 1998 12: 2006–2014

    Article  CAS  Google Scholar 

  13. Heid CA, Stevens J, Livak KJ, Williams PM . Real time quantitative PCR Genome Res 1996 6: 986–994

    Article  CAS  Google Scholar 

  14. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T . Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR Br J Haematol 1998 102: 768–774

    Article  CAS  Google Scholar 

  15. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA . LightCycler Technology for the quantification of bcr/abl fusion transcripts Cancer Res 1999 59: 3171–3174

    CAS  PubMed  Google Scholar 

  16. Taube T, Seeger K, Beyermann B, Hanel C, Duda S, Linderkamp C, Henze G . Multiplex PCR for simultaneous detection of the most frequent T cell receptor-delta gene rearrangements in childhood ALL Leukemia 1997 11: 1978–1982

    Article  CAS  Google Scholar 

  17. Ririe KM, Rasmussen RP, Wittwer CT . Product differentiation by analysis of DNA melting curves during the polymerase chain reaction Anal Biochem 1997 245: 154–160

    Article  CAS  Google Scholar 

  18. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP . Continuous fluorescence monitoring of rapid cycle DNA amplification Biotechniques 1997 22: 130–131

    Article  CAS  Google Scholar 

  19. Holland PM, Abramson RD, Watson R, Gelfand DH . Detection of specific polymerase chain reaction product by utilizing the 5′–3′ exonuclease activity of Thermus aquaticus DNA polymerase Proc Natl Acad Sci USA 1991 88: 7276–7280

    Article  CAS  Google Scholar 

  20. Caplin BERR, Bernard PS, Wittwer CT . The most direct way to monitor PCR amplification and mutation detection Biochemica 1999 1: 5–8

    Google Scholar 

  21. De Silva DRA, Herrmann M, Tabiti K, Wittwer C . Rapid geno-typing and quantification on the LightCycler with hybridization probes Biochemica Information 1998 102: 9–12

    Google Scholar 

Download references

Acknowledgements

This work was kindly supported by the Deutsche Leukämie Forschungshilfe (DLFH) Germany, and by TIB MOLBIOL, Berlin. We thank Claudia Hanel, Gabriele Schmitt and Lucia Badiali for expert technical assistance, for the committed support.

Author information

Authors and Affiliations

  1. Charité Campus Virchow-Klinikum, Childrens Hospital, Berlin, Germany

    C Eckert, T Taube, K Seeger, B Beyermann, J Proba & G Henze

  2. TIB MOLBIOL, Berlin, Germany

    O Landt

Authors
  1. C Eckert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Landt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Taube
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Seeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Beyermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Proba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eckert, C., Landt, O., Taube, T. et al. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 14, 316–323 (2000). https://doi.org/10.1038/sj.leu.2401655

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401655

Keywords

This article is cited by

Search

Advanced search

Quick links